Treatment of Guillain-Barré Syndrome

Hughes, Richard

doi:10.1007/978-1-4471-3175-5_8

Cited by 17 publications

(18 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They presented a large alteration in motor nerve conduction velocity with conduction block despite an absence of motor deficit. The pure sensory form has been considered as a different entity,20 30 33 The cranial nerves were involved in 23 4% of patients, a slightly higher frequency than that reported in previous series. '3 2' We did not find papilloedema, which has been reported in other studies, such as that by Dyck et al21 who found it in 7% of cases.…”

Section: Discussionmentioning

confidence: 89%

Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients.

Maisonobe

Chassande

Vérin

et al. 1996

Journal of Neurology, Neurosurgery & Psychiatry

112

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 89%

Chronic dysimmune demyelinating polyneuropathy: a clinical and electrophysiological study of 93 patients.

Maisonobe

Chassande

Vérin

et al. 1996

Journal of Neurology, Neurosurgery & Psychiatry

112

View full text Add to dashboard Cite

“…Since serious and sometimes life threatening conditions occur and long periods of hospitalization and rehabilitation are often necessary, specific therapy and supportive care is important for GBS patients. Supportive measures are still the mainstay of therapy, but in addition, plasmapheresis and intravenous immunoglobulin are promising therapeutic modalities ( 13,14). Firm evidence …”

Section: Discussionmentioning

confidence: 99%

Intravenous Immunoglobulin Treatment in Children with Guillain-Barre Syndrome

Gürses

Uysal

Çetinkaya

et al. 1995

Scandinavian Journal of Infectious Diseases

View full text Add to dashboard Cite

Guillain-Barre syndrome is an acquired demyelinating polyneuropathy that is presumed to be immune-mediated. On the basis of this assumption, intravenous immunoglobulin (IVIG) has been used in the treatment of Guillain-Barre syndrome in recent years and found to be effective. To test this we performed a randomized study in patients with Guillain-Barre syndrome by giving IVIG (1 g/kg body weight per day over 2 consecutive days) in 9 children who were compared with 9 patients who were observed but not given specific therapy. We concluded that intravenous immunoglobulin is a safe and effective treatment for childhood Guillain-Barre syndrome which shortens the time to recovery.

show abstract

“…Among polyneuropathies, they chiefly comprise the recurrent form of GuillainBarré syndrome (GBS) (1-10% of cases in reported GBS series) 5 and the more common relapsing form of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Mononeuropathy and multifocal mononeuropathy precipitated by trivial trauma are occasionally due to hereditary neuropathy with liability to pressure palsy (HNPP).…”

Section: Accepted 1 March 1997mentioning

confidence: 99%